Perrigo Plays Customary Card For Approval Of First OTC Ibuprofen-Acetaminophen Generic In US

08 Mar 2023

• By Bob Kronemyer

First generic of Haleon Advil Dual Action approved as brand lost three-year market exclusivity and day after Perrigo announced end of phase 1 of turnaround strategy and start of starting phase 2.

As Perrigo Company PLC looks ahead in its transformation, it leverages its traditional strength of being first to launch generics of OTC brands for its latest portfolio expansion.

The Dublin-based firm on 1 March announced approval from the US Food and Drug Administration for OTC 125-mg ibuprofen and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Euro Q2 Consumer Health Earnings Preview: Reckitt, Haleon, Bayer

23 Jul 2025

• By Tom Gallen

Major Europe-based consumer health players Reckitt, Haleon and Bayer feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q2 2025 results over the coming weeks.

People On The Move: Appointments at BioGaia, Assosalute, Bayer

22 Jul 2025

• By Tom Gallen

A round-up of the latest European people moves: BioGaia hires new subsidiary head from L'Oréal; Assosalute gets new director; Bayer renews contract of CEO.

Green Regulation Is ‘A Baseline Not A Burden’ – Behind Opella’s B Corp Journey

21 Jul 2025

• By David Ridley

“For us, regulation is the floor, not the ceiling,” Opella's chief sustainability officer Marissa Saretsky tells HBW Insight as the firm gains B Corp Certification. Other topics covered in this exclusive interview include Opella's position on the revised Urban Wastewater Treatment Directive.